Sintilimab plus a bevacizumab biosimilar versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma: updated results from the ORIENT-32 randomized phase 2–3 trial
已取消
20
由 123 发布于 2026/8/10 16:22:25
文献类型：期刊论文
补充材料：只需要正文
管理员驳回:超时未应助，系统关闭。如求助信息不完整（标题、DOI、原文链接），可以补充后重新发布求助。
补充材料：只需要正文
管理员驳回:超时未应助，系统关闭。如求助信息不完整（标题、DOI、原文链接），可以补充后重新发布求助。
其它数据库
上一个求助:
其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary
下一个求助:
ElsevierEffects of sintilimab plus chemotherapy as first-line treatment on health-related quality of life in patients with advanced esophageal squamous cell carcinoma: results from the randomized phase 3 ORIENT-15 study.
其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary
下一个求助:ElsevierEffects of sintilimab plus chemotherapy as first-line treatment on health-related quality of life in patients with advanced esophageal squamous cell carcinoma: results from the randomized phase 3 ORIENT-15 study.
京公网安备 11010802042870号
